Safety first
Educational only. Not medical advice. Duration of HRT is an individualized clinical decision. Do not stop HRT abruptly without discussing a tapering strategy.
Overview
The “5 year rule” for HRT has no basis in evidence. It is an artifact of post-WHI panic, not clinical science. NAMS does not recommend a maximum duration. The Endocrine Society does not recommend a maximum duration. ACOG does not recommend a maximum duration. Yet clinicians continue to pull women off HRT at arbitrary timelines, sometimes sending them back into the symptoms they spent years managing, plus accelerated bone loss as a parting gift.
If your clinician tells you it is time to stop because you have been on HRT for 5 years, the correct response is: “What is the clinical basis for that decision for my specific situation?”
Key Takeaways
- There is no evidence-based maximum duration for HRT
- Duration should be reassessed annually based on ongoing symptoms, emerging risk factors, and the individual benefit-risk balance
- Vasomotor symptoms persist for a median of 7.4 years and for some women last 10+ years
- Bone-protective benefits of HRT are maintained only during use and lost after discontinuation - approximately 3 to 5% bone mineral density loss in the first 1 to 2 years after stopping
- Low-dose vaginal estrogen for genitourinary symptoms can be used indefinitely with no recommended duration limit
- If stopping, gradual tapering is preferred over abrupt discontinuation
What Happens To Your Bones When You Stop
Bone mineral density declines at accelerated rates after HRT discontinuation - approximately 3-5% loss in the first 1-2 years, comparable to the rapid bone loss of early postmenopause. Women who have been on HRT partly for bone protection can lose years of accumulated benefit in months.
NAMS and the Endocrine Society are clear: women who stop HRT and have osteoporosis risk factors should transition to a bone-specific agent (bisphosphonates or denosumab). Simply stopping without a bone protection plan is a clinical failure. If you are considering stopping, ask your clinician to order a DEXA scan before and 1-2 years after discontinuation to track the impact.
Three Approaches To Duration
Symptom-based continuation. Continue as long as symptoms persist and the benefit-risk balance is favorable. Reassess annually. This is the NAMS-aligned approach.
Periodic trial discontinuation. After 3 to 5 years, gradually taper over 3 to 6 months to see whether symptoms return. If they do, resume. If they do not, you may have naturally moved past the symptomatic window.
Indefinite continuation with dose optimization. For women with persistent symptoms, strong bone protection indication, or cardiovascular benefit from early-initiated therapy, continuing at the lowest effective dose may be appropriate indefinitely. Annual reassessment still applies.
There is no wrong choice among these three. The wrong choice is stopping because someone told you 5 years is the maximum without evaluating your individual situation.
The Vaginal Estrogen Exception
Low-dose vaginal estrogen has no recommended maximum duration. Systemic absorption is minimal. The symptoms it treats are progressive without treatment. NAMS, ACOG, and the Endocrine Society all support continuing vaginal estrogen indefinitely. If you stop systemic HRT, continue vaginal estrogen. This should be a separate, explicit decision.
Questions To Ask A Clinician
- Is there a clinical reason to stop HRT now, or are we stopping because of an arbitrary timeline?
- If my symptoms persist, what is the benefit-risk balance of continuing?
- If I stop, what happens to my bone density, and what is the transition plan?
- If symptoms return after stopping, can I restart?
- Should I continue vaginal estrogen regardless of what we do with systemic HRT?